NO317061B1 - Farmasoytisk preparat for parenteral administrering omfattende amiodaron eller et farmasoytisk akseptabelt salt derav - Google Patents
Farmasoytisk preparat for parenteral administrering omfattende amiodaron eller et farmasoytisk akseptabelt salt derav Download PDFInfo
- Publication number
- NO317061B1 NO317061B1 NO19976125A NO976125A NO317061B1 NO 317061 B1 NO317061 B1 NO 317061B1 NO 19976125 A NO19976125 A NO 19976125A NO 976125 A NO976125 A NO 976125A NO 317061 B1 NO317061 B1 NO 317061B1
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical preparation
- stated
- buffer solution
- solution
- preparation
- Prior art date
Links
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229960005260 amiodarone Drugs 0.000 title claims abstract description 13
- 238000007911 parenteral administration Methods 0.000 title claims abstract description 13
- 150000003839 salts Chemical class 0.000 title claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- 239000007853 buffer solution Substances 0.000 claims abstract description 27
- 239000004094 surface-active agent Substances 0.000 claims abstract description 20
- 239000000243 solution Substances 0.000 claims description 55
- 238000002360 preparation method Methods 0.000 claims description 53
- 229960003234 amiodarone hydrochloride Drugs 0.000 claims description 46
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 38
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 16
- 235000011007 phosphoric acid Nutrition 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
- 229920000053 polysorbate 80 Polymers 0.000 claims description 9
- 229940068968 polysorbate 80 Drugs 0.000 claims description 9
- -1 alkali metal acetate Chemical class 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229910001463 metal phosphate Inorganic materials 0.000 claims description 5
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 5
- 239000008351 acetate buffer Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 150000002433 hydrophilic molecules Chemical class 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 239000003223 protective agent Substances 0.000 claims description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- 230000003381 solubilizing effect Effects 0.000 abstract description 2
- 230000010412 perfusion Effects 0.000 description 17
- 239000000872 buffer Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 12
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 8
- 235000019799 monosodium phosphate Nutrition 0.000 description 8
- 239000003182 parenteral nutrition solution Substances 0.000 description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 8
- 239000001488 sodium phosphate Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000003708 ampul Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DZRJNLPOTUVETG-UHFFFAOYSA-N 1-benzofuran-2-yl(phenyl)methanone Chemical class C=1C2=CC=CC=C2OC=1C(=O)C1=CC=CC=C1 DZRJNLPOTUVETG-UHFFFAOYSA-N 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 239000004990 Smectic liquid crystal Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9507939A FR2735978B1 (fr) | 1995-06-30 | 1995-06-30 | Composition pharmaceutique d'amiodarone pour administration parenterale |
| PCT/FR1996/001010 WO1997002031A1 (fr) | 1995-06-30 | 1996-06-28 | Composition pharmaceutique d'amiodarone pour administration parenterale |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO976125D0 NO976125D0 (no) | 1997-12-29 |
| NO976125L NO976125L (no) | 1998-02-26 |
| NO317061B1 true NO317061B1 (no) | 2004-08-02 |
Family
ID=9480596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19976125A NO317061B1 (no) | 1995-06-30 | 1997-12-29 | Farmasoytisk preparat for parenteral administrering omfattende amiodaron eller et farmasoytisk akseptabelt salt derav |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6143778A (de) |
| EP (1) | EP0835105B1 (de) |
| JP (1) | JP3137987B2 (de) |
| AT (1) | ATE213940T1 (de) |
| AU (1) | AU6462596A (de) |
| BR (1) | BR9609666A (de) |
| CA (1) | CA2222304C (de) |
| DE (1) | DE69619673T2 (de) |
| ES (1) | ES2174083T3 (de) |
| FR (1) | FR2735978B1 (de) |
| MX (1) | MX9710206A (de) |
| NO (1) | NO317061B1 (de) |
| WO (1) | WO1997002031A1 (de) |
| ZA (1) | ZA965525B (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7339078B2 (en) * | 1995-03-10 | 2008-03-04 | G.D. Searle Llc | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| US6861539B1 (en) | 1995-03-10 | 2005-03-01 | G. D. Searle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| FR2764800B1 (fr) * | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
| US6479541B1 (en) | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
| US6646195B1 (en) * | 2000-04-12 | 2003-11-11 | Microsoft Corporation | Kernel-mode audio processing modules |
| US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
| US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| US20020143051A1 (en) | 2001-03-29 | 2002-10-03 | Doty Mark J. | Premixed amiodarone parenteral solution and method for making the same |
| RU2003131686A (ru) * | 2001-03-29 | 2005-01-27 | Бакстер Интернэшнл Инк. (Us) | Предварительно смешанный раствор амиодарона для парентерального введения и способ его получения |
| US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| CA2451839C (en) * | 2001-06-22 | 2013-08-06 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions comprising peptides and permeation enhancers |
| JP2005504090A (ja) | 2001-09-26 | 2005-02-10 | バクスター・インターナショナル・インコーポレイテッド | 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製 |
| US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| JP5296314B2 (ja) * | 2003-07-17 | 2013-09-25 | バナー ファーマキャップス，インコーポレイティド | 制御放出製剤 |
| CA2536283A1 (en) * | 2003-08-20 | 2005-03-03 | Ajinomoto Co., Inc. | Pharmaceutical preparations having an improved solubility |
| CN1926071B (zh) | 2004-04-26 | 2012-02-22 | 三菱麻铁里亚尔株式会社 | 还原性水净化材料、用于生产还原性水净化材料的方法、用于处理废水的方法和废水处理设备 |
| US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| JP5584486B2 (ja) * | 2009-02-16 | 2014-09-03 | 株式会社クラレ | バラスト水製造装置 |
| EP2335686A1 (de) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | Wässrige intravenöse Nanosuspension mit minimalen Nebenwirkungen |
| US20120142768A1 (en) | 2010-06-11 | 2012-06-07 | Baxter Healthcare S.A. | Formulations including amiodarone and salts thereof and methods of their manufacture and use |
| WO2015182647A1 (ja) * | 2014-05-28 | 2015-12-03 | 武田薬品工業株式会社 | 抗菌水 |
| US11077050B2 (en) | 2017-03-24 | 2021-08-03 | Merck Sharp & Dohme Corp. | Formulation for parenteral administration |
| US20220016070A1 (en) * | 2020-07-17 | 2022-01-20 | Good Health, Llc | Premixed, ready to use pharmaceutical compositions of amiodarone |
| CN112472668B (zh) * | 2020-10-29 | 2023-02-28 | 太阳升(亳州)生物医药科技有限公司 | 用于制备盐酸胺碘酮注射液的方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5234949A (en) * | 1992-04-01 | 1993-08-10 | Academic Pharmaceuticals, Inc. | Parenteral solutions containing amiodarone in acetate buffer solution |
-
1995
- 1995-06-30 FR FR9507939A patent/FR2735978B1/fr not_active Expired - Fee Related
-
1996
- 1996-06-28 DE DE69619673T patent/DE69619673T2/de not_active Expired - Lifetime
- 1996-06-28 BR BR9609666A patent/BR9609666A/pt not_active IP Right Cessation
- 1996-06-28 AU AU64625/96A patent/AU6462596A/en not_active Abandoned
- 1996-06-28 EP EP96924037A patent/EP0835105B1/de not_active Expired - Lifetime
- 1996-06-28 MX MX9710206A patent/MX9710206A/es unknown
- 1996-06-28 JP JP09504867A patent/JP3137987B2/ja not_active Expired - Fee Related
- 1996-06-28 CA CA002222304A patent/CA2222304C/fr not_active Expired - Fee Related
- 1996-06-28 AT AT96924037T patent/ATE213940T1/de active
- 1996-06-28 ZA ZA9605525A patent/ZA965525B/xx unknown
- 1996-06-28 ES ES96924037T patent/ES2174083T3/es not_active Expired - Lifetime
- 1996-06-28 WO PCT/FR1996/001010 patent/WO1997002031A1/fr active IP Right Grant
- 1996-06-28 US US08/981,634 patent/US6143778A/en not_active Expired - Lifetime
-
1997
- 1997-12-29 NO NO19976125A patent/NO317061B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0835105B1 (de) | 2002-03-06 |
| FR2735978A1 (fr) | 1997-01-03 |
| FR2735978B1 (fr) | 1997-09-19 |
| NO976125L (no) | 1998-02-26 |
| CA2222304C (fr) | 2002-09-17 |
| WO1997002031A1 (fr) | 1997-01-23 |
| CA2222304A1 (fr) | 1997-01-23 |
| MX9710206A (es) | 1998-03-31 |
| DE69619673T2 (de) | 2002-11-14 |
| EP0835105A1 (de) | 1998-04-15 |
| BR9609666A (pt) | 1999-05-25 |
| NO976125D0 (no) | 1997-12-29 |
| US6143778A (en) | 2000-11-07 |
| AU6462596A (en) | 1997-02-05 |
| JPH10510297A (ja) | 1998-10-06 |
| ZA965525B (en) | 1997-12-29 |
| ATE213940T1 (de) | 2002-03-15 |
| ES2174083T3 (es) | 2002-11-01 |
| DE69619673D1 (de) | 2002-04-11 |
| JP3137987B2 (ja) | 2001-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317061B1 (no) | Farmasoytisk preparat for parenteral administrering omfattende amiodaron eller et farmasoytisk akseptabelt salt derav | |
| US20100120908A1 (en) | Eye drop preparation comprising latanoprost | |
| KR101861163B1 (ko) | 안과용 약학 조성물 | |
| JPH07206709A (ja) | 高濃度免疫グロブリン製剤及びその製造方法 | |
| JPH02264716A (ja) | トラニラスト水溶液製剤 | |
| CA2210076C (en) | Enrofloxacin injection or infusion solutions | |
| US6939865B2 (en) | Pharmaceutical dronedarone composition for parenteral administration | |
| FI117160B (fi) | Nestemäiset HCG-koostumukset | |
| RU2698456C2 (ru) | Офтальмологический гель биматопроста, который наносится в виде капель | |
| JPH11302197A (ja) | ヒアルロン酸安定化組成物 | |
| NO322334B1 (no) | Lyofilisert preparat av human benmorfogenetisk faktor MP52, og fremgangsmate for fremstilling av et lyofilisert preparat av human benmorfogenetisk faktor MP52 | |
| US11439589B2 (en) | Emulsion eyedrops | |
| WO2002017932A1 (fr) | Preparations d'oct | |
| RU2095061C1 (ru) | Фармацевтическая композиция | |
| US8679511B2 (en) | In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts | |
| JP2017503841A (ja) | ウイルス性結膜炎に対し有効な組成物 | |
| JP2023505255A (ja) | 眼科用医薬組成物 | |
| US20030139468A1 (en) | Amiodarone solutions suitable for intravenous administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |